Chief investigator Professor Alan Burnett, from Cardiff Universitys School of Medicine, commented on the findings:
These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.
Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years.
More top news
A study into the effects on LSD on the brain could aid the treatment of depression, the government's former drugs tsar has said.
Plumbers and heating engineers should be trained to help people living in homes that are too cold, according to new health guidelines.
Rain for the northwest, dry and cold elsewhere